153 related articles for article (PubMed ID: 11759055)
1. Specific but variable expression of h-caldesmon in leiomyosarcomas: an immunohistochemical reassessment of a novel myogenic marker.
Hisaoka M; Wei-Qi S; Jian W; Morio T; Hashimoto H
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):302-8. PubMed ID: 11759055
[TBL] [Abstract][Full Text] [Related]
2. Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma.
Sakamoto A; Oda Y; Yamamoto H; Oshiro Y; Miyajima K; Itakura E; Tamiya S; Honda Y; Ishihara A; Iwamoto Y; Tsuneyoshi M
Virchows Arch; 2002 Apr; 440(4):404-9. PubMed ID: 11956822
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue.
Perez-Montiel MD; Plaza JA; Dominguez-Malagon H; Suster S
Am J Dermatopathol; 2006 Apr; 28(2):105-11. PubMed ID: 16625070
[TBL] [Abstract][Full Text] [Related]
4. [Immunohistochemical differentiation of leiomyocellular tumors and tumors with myogenic differentiation].
Povýsil C; Ciprová V; Dundr P; Horáková M
Cesk Patol; 2003 Apr; 39(2):64-8. PubMed ID: 12874903
[TBL] [Abstract][Full Text] [Related]
5. Is anti-h-caldesmon useful for distinguishing smooth muscle and myofibroblastic tumors? An immunohistochemical study.
Ceballos KM; Nielsen GP; Selig MK; O'Connell JX
Am J Clin Pathol; 2000 Nov; 114(5):746-53. PubMed ID: 11068549
[TBL] [Abstract][Full Text] [Related]
6. Calponin and h-caldesmon in soft tissue tumors: consistent h-caldesmon immunoreactivity in gastrointestinal stromal tumors indicates traits of smooth muscle differentiation.
Miettinen MM; Sarlomo-Rikala M; Kovatich AJ; Lasota J
Mod Pathol; 1999 Aug; 12(8):756-62. PubMed ID: 10463476
[TBL] [Abstract][Full Text] [Related]
7. Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors.
Robin YM; Penel N; Pérot G; Neuville A; Vélasco V; Ranchère-Vince D; Terrier P; Coindre JM
Mod Pathol; 2013 Apr; 26(4):502-10. PubMed ID: 23174934
[TBL] [Abstract][Full Text] [Related]
8. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors.
Nucci MR; O'Connell JT; Huettner PC; Cviko A; Sun D; Quade BJ
Am J Surg Pathol; 2001 Apr; 25(4):455-63. PubMed ID: 11257619
[TBL] [Abstract][Full Text] [Related]
9. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies.
Oliva E; Young RH; Amin MB; Clement PB
Am J Surg Pathol; 2002 Apr; 26(4):403-12. PubMed ID: 11914617
[TBL] [Abstract][Full Text] [Related]
10. Pseudosarcomatous myofibroblastic tumor and myosarcoma of the urogenital tract.
Watanabe K; Baba K; Saito A; Hoshi N; Suzuki T
Arch Pathol Lab Med; 2001 Aug; 125(8):1070-3. PubMed ID: 11473460
[TBL] [Abstract][Full Text] [Related]
11. H-caldesmon expression in myofibroblastoma of the breast: evidence supporting the distinction from leiomyoma.
Magro G; Gurrera A; Bisceglia M
Histopathology; 2003 Mar; 42(3):233-8. PubMed ID: 12605642
[TBL] [Abstract][Full Text] [Related]
12. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma.
Loddenkemper C; Mechsner S; Foss HD; Dallenbach FE; Anagnostopoulos I; Ebert AD; Stein H
Am J Surg Pathol; 2003 Nov; 27(11):1458-62. PubMed ID: 14576480
[TBL] [Abstract][Full Text] [Related]
13. h-Caldesmon in leiomyosarcoma and tumors with smooth muscle cell-like differentiation: its specific expression in the smooth muscle cell tumor.
Watanabe K; Kusakabe T; Hoshi N; Saito A; Suzuki T
Hum Pathol; 1999 Apr; 30(4):392-6. PubMed ID: 10208459
[TBL] [Abstract][Full Text] [Related]
14. h-Caldesmon as a specific marker of smooth muscle cell differentiation in some soft tissue tumors of the skin.
D'Addario SF; Morgan M; Talley L; Smoller BR
J Cutan Pathol; 2002 Aug; 29(7):426-9. PubMed ID: 12139638
[TBL] [Abstract][Full Text] [Related]
15. h-Caldesmon as a specific marker for smooth muscle tumors. Comparison with other smooth muscle markers in bone tumors.
Watanabe K; Tajino T; Sekiguchi M; Suzuki T
Am J Clin Pathol; 2000 May; 113(5):663-8. PubMed ID: 10800398
[TBL] [Abstract][Full Text] [Related]
16. A tale of two clones: Caldesmon staining in the differentiation of cutaneous spindle cell neoplasms.
Beck EM; Bauman TM; Rosman IS
J Cutan Pathol; 2018 Aug; 45(8):581-587. PubMed ID: 29687929
[TBL] [Abstract][Full Text] [Related]
17. Vascular leiomyosarcoma: Clinicopathology and immunohistochemistry with special reference to a unique smooth muscle phenotype.
Matsuyama A; Hisaoka M; Hashimoto H
Pathol Int; 2010 Mar; 60(3):212-6. PubMed ID: 20403047
[TBL] [Abstract][Full Text] [Related]
18. Expression of smooth muscle markers in so called malignant fibrous histiocytomas.
Hasegawa T; Hasegawa F; Hirose T; Sano T; Matsuno Y
J Clin Pathol; 2003 Sep; 56(9):666-71. PubMed ID: 12944549
[TBL] [Abstract][Full Text] [Related]
19. Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value.
Demicco EG; Boland GM; Brewer Savannah KJ; Lusby K; Young ED; Ingram D; Watson KL; Bailey M; Guo X; Hornick JL; van de Rijn M; Wang WL; Torres KE; Lev D; Lazar AJ
Histopathology; 2015 Apr; 66(5):627-38. PubMed ID: 24889065
[TBL] [Abstract][Full Text] [Related]
20. Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus.
de Leval L; Waltregny D; Boniver J; Young RH; Castronovo V; Oliva E
Am J Surg Pathol; 2006 Mar; 30(3):319-27. PubMed ID: 16538051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
